Why did PDSB's operating expenses drop sharply in Q4 2024?

PDS Biotechnology Corporation (PDSB) did not report any operating expenses in the fiscal quarter ending Q4 2024. However, it is important to note that the company's net loss for the year ended December 31, 2024, was $37.6 million, which includes all the expenses associated with the company's operations. The reduction in net loss for the year 2024 compared to the previous year can be attributed to decreased operating expenses, particularly in research and development, which fell by $5.2 million. This decrease in operating expenses, along with a decrease in general and administrative expenses, contributed to the overall reduction in losses. In summary, PDSB's operating expenses, including research and development and general and administrative expenses, decreased in Q4 2024, which led to a reduction in the company's net loss for the year.